drugset / Trial / NCT00123305
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-05
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ocriplasmin | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Comparator | Ocriplasmin | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Comparator | Ocriplasmin | Protein / enzyme biologic | 3 mg/kg | Intravenous |